Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)
Curatis reported its strongest half-year to date: H1 2026 net sales from goods and services rose 51% to CHF 7.9m (H1 2025: CHF 5.2m), while the period loss narrowed to CHF -0.4m from CHF -1.2m. Cash and cash equivalents more than doubled to CHF 3.6m, boosted by a CHF 3.0 million convertible instrument placed with a strategic Swiss investor in May 2026 and converted into equity during the reporting period. The corticorelin (C-PTBE-01) program for peritumoral brain edema advanced with an exclusive Japan licence to Neupharma worth up to CHF 83.5m in upfront and milestone payments plus royalties of up to 20% — Curatis' first regional partnership for the program.
Key figures
- Revenue
- CHF 7.9m
- Guidance
- FY2026 revenues of approximately CHF 15m confirmed (2025: CHF 10.8m, ~40% growth); objective remains a break-even result in 2026
- Revenue Yoy
- 51%
- Deal Value Usd
- up to CHF 83.5m (Neupharma Japan licence, upfront and milestone payments; CHF not USD)
- Cash
- CHF 3.6m at 30 June 2026 (31 Dec 2025: CHF 1.9m)
- Net loss
- CHF -0.4m (H1 2025: CHF -1.2m)
- Net sales goods
- CHF 7.4m, +46%
- Operating result
- -401 kCHF (H1 2025: -1,291 kCHF, +69%)
- Ptbe us patients
- >150,000
- Gross contribution
- CHF 1.8m, +32%
- Gross margin goods
- 22.4% (H1 2025: 20.7%)
- Net sales services
- CHF 0.6m (H1 2025: CHF 0.2m)
- Operating cash flow
- CHF -0.9m
- Convertible financing
- CHF 3.0m convertible placed with a strategic Swiss investor in May 2026, converted into equity
- Japan licence royalty
- up to 20%
- Fda phase3 design meeting
- Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.